| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Metabotropic glutamate receptor 3 (mGluR3) and protein kinase C (PKC). β-N-methylamino-L-alanine hydrochloride activates mGluR3, a G protein-coupled receptor that modulates synaptic transmission, and inhibits PKC, a family of enzymes involved in various signaling pathways. Its neurotoxic effects are thought to be mediated through these interactions, leading to excitotoxicity and oxidative stress.
|
|---|---|
| ln Vitro |
In vitro, BMAA has been shown to be toxic to neurons and other cell types. It activates mGluR3 and inhibits PKC. Its neurotoxicity can be assessed by measuring cell viability, markers of oxidative stress, and apoptosis in neuronal cell cultures.
|
| ln Vivo |
In vivo, BMAA has been shown to cause neurotoxicity in animal models. It has been associated with the development of ALS-like symptoms and other neurodegenerative changes in primates and rodents.
|
| Enzyme Assay |
The activity of BMAA can be assessed using receptor binding and enzyme activity assays. Its ability to activate mGluR3 can be measured by monitoring downstream signaling pathways, such as calcium mobilization or cAMP production. Its inhibition of PKC can be measured using a kinase activity assay.
|
| Cell Assay |
To study its neurotoxic effects, neuronal cell lines or primary neurons are treated with BMAA. Cell viability is measured using MTT or LDH release assays. Markers of oxidative stress, such as reactive oxygen species (ROS) and lipid peroxidation, are measured.
|
| Animal Protocol |
BMAA is administered to animals via intraperitoneal injection or oral gavage to study its neurotoxic effects. The animals are monitored for behavioral changes, and their brains are analyzed for neuropathological changes, such as neuronal loss and protein aggregation.
|
| ADME/Pharmacokinetics |
β-N-methylamino-L-alanine hydrochloride has a molecular weight of 154.60 g/mol and a molecular formula of C4H11ClN2O2. It is a water-soluble solid. It is typically stored at -20°C.
|
| Toxicity/Toxicokinetics |
BMAA is a potent neurotoxin. It is a hazardous compound and must be handled with extreme care. Appropriate personal protective equipment (PPE) and containment measures should be used to prevent exposure.
|
| References | |
| Additional Infomation |
See other relationships...
β-N-methylamino-L-alanine hydrochloride is a research compound used to study the potential link between environmental toxins and neurodegenerative diseases. It is a valuable tool for investigating the mechanisms of neurotoxicity and for developing potential therapeutic interventions. It is not a drug and is not approved for any therapeutic use. |
| Molecular Formula |
C4H11CLN2O2
|
|---|---|
| Molecular Weight |
154.60
|
| Exact Mass |
154.05
|
| CAS # |
16012-55-8
|
| PubChem CID |
51358333
|
| Appearance |
White to yellow solid powder
|
| LogP |
0.51
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
84.1
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CNC[C@@H](C(=O)O)N.Cl
|
| InChi Key |
VDXYGASOGLSIDM-DFWYDOINSA-N
|
| InChi Code |
InChI=1S/C4H10N2O2.ClH/c1-6-2-3(5)4(7)8;/h3,6H,2,5H2,1H3,(H,7,8);1H/t3-;/m0./s1
|
| Chemical Name |
(2S)-2-amino-3-(methylamino)propanoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 31.25 mg/mL (202.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (161.71 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4683 mL | 32.3415 mL | 64.6831 mL | |
| 5 mM | 1.2937 mL | 6.4683 mL | 12.9366 mL | |
| 10 mM | 0.6468 mL | 3.2342 mL | 6.4683 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
